β-blockers in the management of hypertension: Focus on nebivolol

Department of Veterans Affairs Medical Center, Georgetown University Medical Center, Washington, DC 20422, USA.
Expert Review of Cardiovascular Therapy 05/2008; 6(4):471-9. DOI: 10.1586/14779072.6.4.471
Source: PubMed


Hypertension is a major cardiovascular risk factor but most patients remain asymptomatic for many years. Successful therapy not only needs to be effective, it also needs to be well tolerated. beta-blockers are well established as effective antihypertensive agents. However, one major drawback to the currently available beta-blockers, particularly the noncardioselective beta-blockers, is their side-effect profile, including sexual dysfunction, fatigue, depression and metabolic abnormalities such as impaired glucose tolerance and lipid abnormalities. Nebivolol (Bystolic), a novel, highly cardioselective, third-generation beta-blocker that recently received approval by the US FDA for the treatment of hypertension in the USA, is effective in treating blood pressure and has a favorable side-effect profile. Studies conducted in Europe, where nebivolol has been available for some time for the treatment of hypertension, have shown that nebivolol achieves blood pressure reductions comparable to other beta-blockers but with fewer side effects. Additionally, nebivolol has demonstrated similar efficacy in blood pressure reduction when compared with calcium channel blockers and inhibitors of the renin-angiotensin system. When combined with hydrochlorothiazide there was an additive antihypertensive effect. Lastly, nebivolol exhibits a vasodilatory property that is related to its effect on nitric oxide, an intrinsic vasodilator produced in the vascular endothelium. Nebivolol enhances nitric oxide bioavailability. Studies have also demonstrated nebivolol's ability to function as an antioxidant and decrease markers of oxidative stress. These effects are believed to ultimately produce a modulation of the endothelial dysfunction typically seen in hypertension.

Download full-text


Available from: Vasilios Papademetriou, Oct 12, 2015
81 Reads
  • Source
    • "In addition, nebivolol exerts systemic antioxidative properties and this effect was hypothesized as an additional factor for increasing NO bioavailability. For example, nebivolol and atenolol similarly reduced blood pressure values in hypertensive patients, but oxidative stress markers, such as LDL hydroperoxides, 8-isoprostanes, ox-LDL were significantly improved only in patients treated with nebivolol (Troost et al., 2000; Fratta Pasini et al., 2005; Wojciechowski and Papademetriou, 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nitric Oxide (NO) is a small molecule that continues to attract much attention from the scientific community. Since its discovery, it has been evident that NO has a crucial role in the modulation of vascular tone. NO is involved in multiple signal transduction pathways thus contributing to the regulation of many cellular functions. NO effects can be either dependent or independent on cGMP, and rely also upon several mechanisms such as the amount of NO, the compartmentalisation of the enzymes responsible for its biosynthesis (NOS), and the local redox conditions. Several evidences highlighted the correlation among adrenoreceptors activity, vascular redox status and NO bioavailability. It was suggested a possible crosstalk between NO and oxidative stress hallmarks in the endothelium function and adaptation, and in sympathetic vasoconstriction control. Adrenergic vasoconstriction is a balance between a direct vasoconstrictive effect on smooth muscle and an indirect vasorelaxant action caused by α2- and β-adrenergic endothelial receptor-triggered NO release. An increased oxidative stress and a reduction of NO bioavailability shifts this equilibrium causing the enhanced vascular adrenergic responsiveness observed in hypertension. The activity of NOS contributes to manage the adrenergic pathway, thus supporting the idea that the endothelium might control or facilitate β-adrenergic effects on the vessels and the polymorphic variants in β2-receptors and NOS isoforms could influence aging, some pathological conditions and individual responses to drugs. This seems to be dependent, almost in part, on differences in the control of vascular tone exerted by NO. Given its involvement in such important mechanisms, the NO pathway is implicated in aging process and in both cardiovascular and non-cardiovascular conditions. Thus, it is essential to pinpoint NO involvement in the regulation of vascular tone for the effective clinical/therapeutic management of cardiovascular diseases.
    Frontiers in Physiology 11/2013; 4(suppl4):321. DOI:10.3389/fphys.2013.00321 · 3.53 Impact Factor
  • Source
    • "Nebivolol is a novel third generation β1-adrenoceptor blocker [17] [18] [19] advocated for the treatment of hypertension . It is unique among all β1-adrenoceptor blockers in that it possesses a vasodilatory property attributed to synthesis of NO [20] [21] as well as to increasing NO bioavailability by decreasing the oxidative stress [22] [23] [24] [25] [26]. "
    Natural Science 01/2010; Vol.2(12):1360-1368. DOI:10.4236/ns.2010.212166
  • [Show abstract] [Hide abstract]
    ABSTRACT: Over-current protection for IGBT (insulated gate bipolar transistor) has created a great amount of attention in recent years. Over-current protection covers both for overload protection and short circuit protection. The protection circuit should be able to distinguish these two fault conditions and its response should be different. However in order to implement proper sensing, comparison and time delay functions, the protection circuit usually becomes complicated where active components and integrated circuits are used. In this paper, a simple IGBT gate drive circuit with only 9 passive and 1 active components was proposed to implement the complete function of over-current protection. The circuit is able to provide a suitable delay time prior to the gate shutdown in order to operate the device closer to but still within the limit of the safe operation area (SOA). The circuit was analysed theoretically and the performance was verified with experimental results.
    Power Electronic Drives and Energy Systems for Industrial Growth, 1998. Proceedings. 1998 International Conference on; 01/1999
Show more